Table 1. Recommended and Alternative Initial ART Regimen
Options for All Patients, Regardless of Pre-ART
Viral Load or CD4 Cell Count
NNRTI-Based Regimen:
EFV/TDF/FTC
a
(AI)
PI-Based Regimens:
ATV/r plus TDF/FTC
a
(AI)
DRV/r plus TDF/FTC
a
(AI)
INSTI-Based Regimens:
DTG plus ABC/3TC
a
(AI) —
ONLY for patients who are
HLA-B*5701 negative
DTG plus TDF/FTC
a
(AI)
EVG/cobi/TDF/FTC —
ONLY for patients with pre-treatment
estimated CrCl ≥70 mL/min (AI)
RAL plus TDF/FTC
a
(AI)
In Addition to the Regimens Listed Above
(the following regimens are also recommended, but only for patients with pre-ART plasma
HIV RNA <100,000 copies/mL)
NNRTI-Based Regimens:
EFV plus ABC/3TC
a
(AI) —
ONLY for patients who are
HLA-B*5701 negative
RPV/TDF/FTC
a
(AI) —
ONLY for patients with CD4 cell
count >200 cells/mm
3
PI-Based Regimen:
ATV/r plus ABC/3TC
a
(AI)—
ONLY for patients who are HLA-B*5701
negative
Alternative Initial ART Regimen Options
(Regimens that are effective and tolerable, but that have potential disadvantages when compared
with the recommended regimens listed above or have less data from randomized clinical trials. An
alternative regimen may be the preferred regimen for some patients.)
PI-Based Regimens:
DRV/r plus ABC/3TC
a
(BII)—
ONLY for patients who are
HLA-B*5701 negative
LPV/r (once
b
or twice daily) plus
ABC/3TC
a
(BI)—
ONLY for patients who are
HLA-B*5701 negative
LPV/r (once
b
or twice daily) plus
TDF/FTC
a
(BI)
INSTI-Based Regimen:
RAL plus ABC/3TC (BII)—
ONLY for patients who are HLA-B*5701
negative
a
3TC may be substituted for FTC or vice versa. e following combinations in the recommended list
above are available as co-formulated fixed-dose combinations: ABC/3TC, EFV/TDF/FTC, EVG/
cobi/TDF/FTC, LPV/r, RPV/TDF/FTC, and TDF/FTC.
b
Once daily LPV/r is not recommended for pregnant patients.
1
